SGMOQ · Sangamo Therapeutics, Inc
$0.16
+0.01 (+4.63%)
At close · Aug 28
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“There is substantial doubt about our ability to continue to operate as a going concern. We will need substantial additional funding in the very near term to execute our operating plan and to continue to operate as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$65.87M
Shares
414.29M
Sangamo Therapeutics, Inc Earnings Call Transcripts
Quarterly earnings calls for Sangamo Therapeutics, Inc (SGMOQ), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲7.4%
$28.23M
−$43.98M
'22 Q1
22-05-05
▲5.4%
$29.38M
−$43.17M
'22 Q2
22-08-04
▼7.4%
$26.46M
−$53.16M
'22 Q3
22-11-03
▼2.7%
$27.23M
−$51.97M
'22 Q4
23-02-22
▲459.5%
$157.96M
$21.13M
'23 Q1
23-04-26
▼76.7%
$6.83M
−$114.51M
'23 Q2
23-08-08
▼64.5%
$9.40M
−$104.16M
'23 Q3
23-11-01
▼92.5%
$2.04M
−$60.30M
'23 Q4
24-03-13
▼99.7%
$481,000
−$49.09M
'24 Q1
24-05-09
▼94.8%
$356,000
−$36.13M
'24 Q2
24-08-06
▲425.8%
$49.41M
$10.67M
'24 Q3
24-11-12
▲269.8%
$7.55M
−$23.40M
'24 Q4
25-03-17
▲5042.1%
$18.31M
−$19.99M
'25 Q2
25-08-07
▼98.8%
$581,000
−$34.93M
'25 Q3
25-11-06
▲88.4%
$14.23M
−$37.42M
'25 Q4
26-03-30
LATEST
▼77.6%
$1.44M
−$31.00M
'26 Q1
26-05-14
Earnings call
FY26 · Q1
2026-05-14
Sangamo Therapeutics, Inc (SGMOQ) Q1 2026 Earnings Call Transcript
Revenue
$1.44M
▼ 77.6% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-30
Sangamo Therapeutics, Inc (SGMOQ) Q4 2025 Earnings Call Transcript
Cautious tone
Fabry BLA submission and CMC progress
Regulatory uncertainty and FDA
Neurology pipeline (ST-503, STAND)
Revenue
$14.23M*
▲ 88.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Sangamo Therapeutics, Inc (SGMOQ) Q3 2025 Earnings Call Transcript
Positive tone
ST-920 Fabry Disease BLA Progress
Neurology Pipeline - STAND Study
Platform Technologies
Revenue
$581,000
▼ 98.8% YoY Diluted EPS
$-0.11
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Sangamo Therapeutics, Inc (SGMOQ) Q2 2025 Earnings Call Transcript
Confident tone
STAAR Fabry registrational data
Neurology pain program (Nav1.7 / STAND)
BLA submission and regulatory pathway
Revenue
$18.31M
▲ 5042.1% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
Sangamo Therapeutics, Inc (SGMOQ) Q4 2024 Earnings Call
Revenue
$7.55M*
▲ 269.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Sangamo Therapeutics, Inc (SGMOQ) Q3 2024 Earnings Call Transcript
Confident tone
Fabry disease regulatory pathway and BLA readiness
Hemophilia A program with Pfizer
Regulatory interactions with FDA and EMA
Revenue
$49.41M
▲ 425.8% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Sangamo Therapeutics, Inc (SGMOQ) Q2 2024 Earnings Call Transcript
Confident tone
Genentech capsid and cargo license deal
Fabry disease program and partnership
Pfizer AFFINE Phase 3 hemophilia A data
Revenue
$356,000
▼ 94.8% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Sangamo Therapeutics, Inc (SGMOQ) Q1 2024 Earnings Call Transcript
Balanced tone
MINT integrase platform
STAC-BBB capsid delivery platform
Business development and partnerships
Revenue
$481,000
▼ 99.7% YoY Diluted EPS
$-0.27
▼ 325% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Sangamo Therapeutics, Inc (SGMOQ) Q4 2023 Earnings Call Transcript
Confident tone
STAC-BBB capsid and blood-brain barrier delivery
Neurology pipeline focus and prion/tau programs
Fabry disease regulatory pathway and partnering
Revenue
$2.04M*
▼ 92.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Sangamo Therapeutics, Inc (SGMOQ) Q3 2023 Earnings Call Transcript
Revenue
$9.40M
▼ 64.5% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Sangamo Therapeutics, Inc (SGMOQ) Q2 2023 Earnings Call Transcript
Revenue
$6.83M
▼ 76.7% YoY Diluted EPS
$-0.66
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-26
Sangamo Therapeutics, Inc (SGMOQ) Q1 2023 Earnings Call Transcript
Revenue
$157.96M
▲ 459.5% YoY Diluted EPS
$0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Sangamo Therapeutics, Inc (SGMOQ) Q4 2022 Earnings Call Transcript
Revenue
$27.23M*
▼ 2.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Sangamo Therapeutics, Inc (SGMOQ) Q3 2022 Earnings Call Transcript
Revenue
$26.46M
▼ 7.4% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Sangamo Therapeutics, Inc (SGMOQ) Q2 2022 Earnings Call Transcript
Revenue
$29.38M
▲ 5.4% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Sangamo Therapeutics, Inc (SGMOQ) Q1 2022 Earnings Call Transcript
Revenue
$28.23M
▲ 7.4% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Sangamo Therapeutics, Inc (SGMOQ) Q4 2021 Earnings Call
Revenue
$27.99M*
▲ 8.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Sangamo Therapeutics, Inc (SGMOQ) Q3 2021 Earnings Call
Revenue
$28.56M
▼ 50.6% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Sangamo Therapeutics, Inc (SGMOQ) Q2 2021 Earnings Call
Revenue
$27.87M
▲ 29.3% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Sangamo Therapeutics, Inc (SGMOQ) Q1 2021 Earnings Call
Revenue
$26.28M
▲ 101% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Sangamo Therapeutics, Inc (SGMOQ) Q4 2020 Earnings Call Transcript
Revenue
$25.80M
▼ 53% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Sangamo Therapeutics, Inc (SGMOQ) Q3 2020 Earnings Call Transcript
Revenue
$57.76M
▲ 163.1% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Sangamo Therapeutics, Inc (SGMOQ) Q2 2020 Earnings Call Transcript
Revenue
$21.55M
▲ 22.8% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Sangamo Therapeutics, Inc (SGMOQ) Q1 2020 Earnings Call Transcript
Revenue
$13.08M
▲ 62% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
Sangamo Therapeutics, Inc (SGMOQ) Q4 2019 Earnings Call
Revenue
$54.85M
▲ 104.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls